海翔药业最新筹码趋于集中

Summary of Key Points Core Viewpoint - Haisheng Pharmaceutical has experienced a decline in the number of shareholders and a decrease in stock price, indicating potential challenges in its financial performance and investor sentiment [2]. Group 1: Shareholder and Stock Performance - As of September 20, the number of shareholders for Haisheng Pharmaceutical was 26,641, a decrease of 2,277 from the previous period (September 10), representing a decline of 7.87% [2]. - The latest stock price for Haisheng Pharmaceutical is 5.88 yuan, remaining flat, with a cumulative decline of 8.13% since the concentration of shares began [2]. - The stock has seen 3 days of increases and 6 days of decreases during this period [2]. Group 2: Financing and Margin Data - As of September 23, the margin trading balance for the stock was 866 million yuan, with a financing balance of 865 million yuan [2]. - The financing balance has decreased by 2.8457 million yuan, reflecting a decline of 0.33% since the concentration of shares began [2]. Group 3: Financial Performance - In the first half of the year, Haisheng Pharmaceutical reported total revenue of 925 million yuan, a year-on-year decrease of 10.94% [2]. - The net profit for the same period was 14.0937 million yuan, down 63.01% year-on-year [2]. - The basic earnings per share were 0.0100 yuan, with a weighted average return on equity of 0.27% [2].